Precipio (PRPO) Competitors

Precipio logo
$19.17 -0.79 (-3.96%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$19.19 +0.02 (+0.11%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRPO vs. XGN, BDSX, PARK, JYNT, and LFMD

Should you buy Precipio stock or one of its competitors? Precipio's main competitors and comparable companies include Exagen (XGN), Biodesix (BDSX), Park Dental Partners (PARK), Joint (JYNT), and LifeMD (LFMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Precipio compare to Exagen?

Exagen (NASDAQ:XGN) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Precipio has a net margin of -4.12% compared to Exagen's net margin of -25.14%. Precipio's return on equity of -7.84% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-25.14% -125.60% -33.46%
Precipio -4.12%-7.84%-5.37%

Exagen presently has a consensus price target of $9.88, indicating a potential upside of 162.63%. Given Exagen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Exagen is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

75.3% of Exagen shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 16.6% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Exagen had 23 more articles in the media than Precipio. MarketBeat recorded 25 mentions for Exagen and 2 mentions for Precipio. Precipio's average media sentiment score of 0.53 beat Exagen's score of 0.41 indicating that Precipio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exagen
6 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Precipio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Precipio has lower revenue, but higher earnings than Exagen. Precipio is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$66.57M1.44-$19.95M-$0.75N/A
Precipio$24.05M1.43-$360K-$0.59N/A

Exagen has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Precipio has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

Exagen beats Precipio on 9 of the 16 factors compared between the two stocks.

How does Precipio compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Precipio has lower revenue, but higher earnings than Biodesix. Precipio is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$88.50M1.11-$35.26M-$2.76N/A
Precipio$24.05M1.43-$360K-$0.59N/A

Precipio has a net margin of -4.12% compared to Biodesix's net margin of -25.74%. Precipio's return on equity of -7.84% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-25.74% -442.34% -29.16%
Precipio -4.12%-7.84%-5.37%

In the previous week, Biodesix had 10 more articles in the media than Precipio. MarketBeat recorded 12 mentions for Biodesix and 2 mentions for Precipio. Precipio's average media sentiment score of 0.53 beat Biodesix's score of 0.14 indicating that Precipio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biodesix
3 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Precipio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biodesix presently has a consensus target price of $34.20, suggesting a potential upside of 285.14%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

21.0% of Biodesix shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 16.6% of Precipio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biodesix has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Precipio has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Summary

Biodesix beats Precipio on 9 of the 17 factors compared between the two stocks.

How does Precipio compare to Park Dental Partners?

Precipio (NASDAQ:PRPO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

10.5% of Precipio shares are held by institutional investors. 16.6% of Precipio shares are held by insiders. Comparatively, 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Park Dental Partners has a consensus target price of $28.50, indicating a potential upside of 47.21%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, Park Dental Partners had 6 more articles in the media than Precipio. MarketBeat recorded 8 mentions for Park Dental Partners and 2 mentions for Precipio. Precipio's average media sentiment score of 0.53 beat Park Dental Partners' score of 0.45 indicating that Precipio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Precipio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Park Dental Partners
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Park Dental Partners has a net margin of -1.21% compared to Precipio's net margin of -4.12%. Park Dental Partners' return on equity of 27.76% beat Precipio's return on equity.

Company Net Margins Return on Equity Return on Assets
Precipio-4.12% -7.84% -5.37%
Park Dental Partners -1.21%27.76%4.20%

Precipio is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$24.05M1.43-$360K-$0.59N/A
Park Dental Partners$244.49M0.44-$360K-$1.91N/A

Summary

Park Dental Partners beats Precipio on 10 of the 15 factors compared between the two stocks.

How does Precipio compare to Joint?

Joint (NASDAQ:JYNT) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Joint currently has a consensus price target of $8.00, indicating a potential upside of 20.30%. Given Joint's stronger consensus rating and higher probable upside, research analysts clearly believe Joint is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Joint
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Joint has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Precipio has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Joint had 7 more articles in the media than Precipio. MarketBeat recorded 9 mentions for Joint and 2 mentions for Precipio. Joint's average media sentiment score of 1.05 beat Precipio's score of 0.53 indicating that Joint is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Joint
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Precipio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Joint has a net margin of 4.81% compared to Precipio's net margin of -4.12%. Joint's return on equity of 22.11% beat Precipio's return on equity.

Company Net Margins Return on Equity Return on Assets
Joint4.81% 22.11% 6.15%
Precipio -4.12%-7.84%-5.37%

Joint has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Joint$54.90M1.66$2.91M$0.2033.25
Precipio$24.05M1.43-$360K-$0.59N/A

76.9% of Joint shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 16.6% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Joint beats Precipio on 14 of the 15 factors compared between the two stocks.

How does Precipio compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

LifeMD has a net margin of -0.25% compared to Precipio's net margin of -4.12%. Precipio's return on equity of -7.84% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMD-0.25% -188.63% -32.24%
Precipio -4.12%-7.84%-5.37%

35.5% of LifeMD shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 16.6% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LifeMD has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Precipio has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

LifeMD presently has a consensus price target of $7.14, suggesting a potential upside of 297.93%. Given LifeMD's stronger consensus rating and higher probable upside, equities analysts clearly believe LifeMD is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

LifeMD has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$194.05M0.45$14.35M-$0.06N/A
Precipio$24.05M1.43-$360K-$0.59N/A

In the previous week, LifeMD had 14 more articles in the media than Precipio. MarketBeat recorded 16 mentions for LifeMD and 2 mentions for Precipio. Precipio's average media sentiment score of 0.53 beat LifeMD's score of 0.06 indicating that Precipio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeMD
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Precipio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

LifeMD beats Precipio on 12 of the 16 factors compared between the two stocks.

Get Precipio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRPO vs. The Competition

MetricPrecipioHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$35.79M$10.88B$7.83B$11.74B
Dividend YieldN/A2.54%2.47%4.47%
P/E Ratio-32.4936.2734.3128.41
Price / Sales1.432.108.495.70
Price / Cash25.1222.8921.0121.90
Price / Book2.313.574.453.72
Net Income-$360K$332.46M$3.52B$393.10M
7 Day Performance-22.70%-4.24%-5.94%-5.77%
1 Month Performance-10.34%-1.72%-4.59%-7.14%
1 Year Performance-18.01%19.25%-1.94%-7.47%

Precipio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRPO
Precipio
0.6649 of 5 stars
$19.17
-4.0%
N/A-8.8%$35.79M$24.05MN/A71
XGN
Exagen
4.0235 of 5 stars
$5.04
-4.2%
$9.88
+95.9%
-55.6%$122.12M$66.57MN/A220
BDSX
Biodesix
3.986 of 5 stars
$10.12
+1.0%
$34.20
+237.9%
+12.1%$112.23M$88.50MN/A334
PARK
Park Dental Partners
3.8538 of 5 stars
$22.07
+2.7%
$28.50
+29.1%
N/A$104.94M$251.37M21.021,212
JYNT
Joint
4.461 of 5 stars
$6.80
-0.4%
$8.00
+17.6%
-19.0%$96.17M$58.72M34.00330

Related Companies and Tools


This page (NASDAQ:PRPO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners